Agios Pharmaceuticals, Inc. (AGIO) |
|
23.26 -0.74 (-3.08%)
|
03-17 16:00 |
|
Open: |
23.89 |
Pre. Close: |
24 |
|
High:
|
23.89 |
Low:
|
22.985 |
|
Volume:
|
753,033 |
Market Cap:
|
1,286(M) |
|
|
|
Technical analysis |
as of: 2023-03-17 4:17:05 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 30.42  One year: 33.97 |
| Support: |
Support1: 21.12 Support2: 17.57 |
| Resistance: |
Resistance1: 26.04 Resistance2: 29.09 |
| Pivot: |
23.76 |
| Moving Average: |
MA(5): 23.27  MA(20): 24.4
MA(100): 27.82 MA(250): 26.21 |
| MACD: |
MACD(12,26): -1.3 Signal(9): -1.4 |
| Stochastic oscillator: |
%K(14,3): 47.1 %D(3): 40.2 |
| RSI: |
RSI(14): 36.9 |
| 52-week: |
High: 34.75 Low: 16.75 |
| Average Vol(K): |
3-Month: 522 (K) 10-Days: 604 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AGIO ] has closed above bottom band by 37.1%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
24.37 - 24.46 |
24.46 - 24.53 |
|
Low:
|
22.89 - 23 |
23 - 23.1 |
|
Close:
|
23.83 - 23.98 |
23.98 - 24.12 |
|
Company Description |
|
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Mon, 13 Mar 2023
Zacks Research Comments on Agios Pharmaceuticals, Inc.'s ... - MarketBeat
Sun, 05 Mar 2023
TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels - Yahoo Finance
Sun, 05 Mar 2023
Macquarie Group Ltd. acquires shares of Agios Pharmaceuticals, Inc ... - Best Stocks
Sat, 04 Mar 2023
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by ... - MarketBeat
Thu, 02 Mar 2023
Agios to Participate in March Investor Conferences - Agios Pharmaceuticals (NASDAQ:AGIO) - Benzinga
Tue, 28 Feb 2023
Agios Launches “Red Cell Revolution” in Recognition of Rare ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
55 (M) |
|
% Held by Insiders
|
5.155e+007 (%) |
|
% Held by Institutions
|
1.3 (%) |
|
Shares Short
|
6,690 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.8048e+008 |
|
EPS Est Next Qtl
|
-1.83 |
|
EPS Est This Year
|
-7.08 |
|
EPS Est Next Year
|
-7.37 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
732 |
|
Return on Equity (ttm)
|
-18.2 |
|
Qtrly Rev. Growth
|
1.424e+007 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-21.06 |
|
EBITDA (p.s.)
|
1.36304e+007 |
|
Qtrly Earnings Growth
|
-4.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-309 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-1.11 |
|
Price to Cash Flow
|
1.06 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
5.78e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
